Sun Pharmaceutical Industries Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Sun Pharmaceutical Industries şirketinin toplam hissedar öz sermayesi ₹693.8B ve toplam borcu ₹20.8B olup, bu da borç-öz sermaye oranını 3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹881.2B ve ₹187.4B dir. Sun Pharmaceutical Industries 'in FAVÖK'ü ₹114.5B faiz karşılama oranı -12.9 dur. Şirketin ₹201.2B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
3.0%
Borç/özkaynak oranı
₹20.81b
Borç
| Faiz karşılama oranı | -12.9x |
| Nakit | ₹201.22b |
| Eşitlik | ₹693.80b |
| Toplam yükümlülükler | ₹187.36b |
| Toplam varlıklar | ₹881.16b |
Son finansal sağlık güncellemeleri
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Recent updates
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: SUNPHARMA 'nin kısa vadeli varlıkları ( ₹461.1B ) kısa vadeli yükümlülüklerini ( ₹172.6B ) aşıyor.
Uzun Vadeli Yükümlülükler: SUNPHARMA şirketinin kısa vadeli varlıkları ( ₹461.1B ) uzun vadeli yükümlülüklerini ( ₹14.8B ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: SUNPHARMA şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: SUNPHARMA 'nin borç/öz sermaye oranı son 5 yılda 15.9% seviyesinden 3% seviyesine düştü.
Borç Kapsamı: SUNPHARMA 'nin borcu işletme nakit akışı ( 611% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: SUNPHARMA ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.